

IN THE CLAIMS:

The following listing of the claims replaces all prior versions:

1. (Currently amended) A method for delaying or reversing a retinal or ~~choroidal~~ choroidal degenerative disease or condition in a subject, the method comprising contacting a retinal or choroidal cell or subretinal space of a subject having, or at risk of developing, a retinal or ~~choroidal~~ choroidal degenerative disease or condition with an agent that modulates the expression or activity of an AMDP-related or phagocytosis-related gene or product thereof.
2. (Currently amended) The method of claim 1, wherein said AMDP-related or phagocytosis-related gene or product thereof is selected from the group consisting of human unknown PHG-1; prostaglandin D2 synthase; myelin basic protein; human unknown PHG-4; human unknown PHG-5; human peanut-like 2/septin 4; coactosin-like 1; clusterin; casein kinase 1 epsilon; ferritin heavy polypeptide 1; metarginin; human unknown PHG-13; retinaldehyde binding protein 1; actin gamma 1; matrix metalloproteinase, membrane-associated 1 (MT1-MMP); SWI/SNF related/OSA-1 nuclear protein; and human unknown AMDP-3; said AMDP-related or phagocytosis-related genes comprising the respective nucleotide sequences identified as SEQ ID NOS:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, and 17.
3. (Original) The method of claim 2, wherein said AMDP-related or phagocytosis-related gene is matrix metalloproteinase, membrane-associated 1 (MT1-MMP), said gene comprising the nucleotide sequence of SEQ ID NO:15.
4. (Currently amended) The method of claim 1, wherein said retinal or ~~choroidal~~ choroidal degenerative disease or condition is age-related macular degeneration (AMD).
5. (Original) The method of claim 4, wherein said subject suffers from AMD.

6. (Original) The method of claim 4, wherein said subject is at risk of developing AMD.
7. (Currently amended) The method of claim 1, wherein the method delays the retinal or choroidalchoroidal degenerative disease or condition.
8. (Currently amended) The method of claim 1, wherein the method reverses the retinal or choroidal choroidal degenerative disease or condition.
9. (Original) The method of claim 1, wherein said cell is a photoreceptor, an RPE cell, a Muller cell, or a cell type of the choroid selected from the group consisting of an endothelial cell, a smooth muscle cell, a leukocyte, a macrophage, a melanocyte and a fibroblast.
10. (Original) The method of claim 9, wherein said AMDP-related or phagocytosis-related gene is MT1-MMP, and said MT1-MMP is located within said cell.
11. (Original) The method of claim 9, wherein said AMDP-related or phagocytosis-related gene is MT1-MMP and said MT1-MMP is located in an extracellular matrix.
12. (Original) The method of claim 11, wherein said extracellular matrix is an interphotoreceptor matrix.
13. (Currently amended) The method of claim 1, wherein said agent down-regulates expression or activity of a nucleic acid or amino acid sequence of an AMDP-related or phagocytosis-related gene, said gene selected from the group consisting of MT1-MMP, prostaglandin D2 synthase and AMDP-3.
14. (Withdrawn) The method of claim 13, wherein said agent is an oligonucleotide selected

Application No. 10/773,446

from the group consisting of a ribozyme, an antisense RNA, an interfering RNA (RNAi) molecule and a triple helix forming molecule.

15. (Original) The method of claim 13, wherein said agent is an antibody that specifically binds to a MT1-MMP, prostaglandin D2 synthase or AMDP-3 protein or peptide.

16. (Original) The method of claim 15, wherein said antibody neutralizes at least one biological activity of MT1-MMP, prostaglandin D2 synthase or AMDP-3.

17. (Original) The method of claim 16, wherein said AMDP-related or phagocytosis-related gene is MT1-MMP and said biological activity is activation of progelatinase A or degradation of extracellular matrix.

18. (Withdrawn) The method of claim 13, wherein said agent is a small molecule.

19. (Withdrawn) A method of determining risk of a subject of developing a retinal or choridal degenerative disease or condition, the method comprising screening a nucleic acid sequence of said subject for the presence of at least one polymorphism in at least one phagocytosis-related or AMDP-related gene, wherein the presence of a polymorphism in at least one of said genes indicates that the subject is at higher risk for developing a retinal or choridal degenerative disease or condition, than a subject without said polymorphism.

20. (Withdrawn) The method of claim 19, wherein said phagocytosis-related gene comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOS:1-17.

21. (Withdrawn) The method of claim 19, wherein said AMDP-related gene comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOS:2, 9, 10, 16, and 17.

22. (Withdrawn) The method of claim 19, wherein said polymorphism is within an intronic, exonic or promoter sequence of said phagocytosis-related or AMDP-related gene.
23. (Withdrawn) The method of claim 19, wherein said polymorphism is within a region of the human MT1-MMP gene that can be amplified by PCR using amplimer pairs having nucleic acid sequences selected from the group consisting of SEQ ID NOS: 18 and 19; 20 and 21; 22 and 23; 24 and 25; 26 and 27; 28 and 29; 30 and 31; 32 and 33; 34 and 35; 36 and 37; 38 and 39; 40 and 41; 42 and 43; 44 and 45; 46 and 47; 48 and 49; 50 and 51; 52 and 53; 54 and 55; 56 and 57; and 57 and 58.
24. (Withdrawn) The method of claim 19, wherein said polymorphism is within a 285 bp fragment of exon 5 of the human MT1-MMP gene.
25. (Withdrawn) The method of claim 24, wherein said polymorphism is a D273N missense polymorphism.
26. (Withdrawn) The method of claim 24, wherein said polymorphism is a P259P synonymous polymorphism.
27. (Withdrawn) A method of treating a retinal or choroidal degenerative disease or condition in a subject, the method comprising contacting a retinal or choroidal cell of said subject with a vector that includes a nucleic acid encoding an agent that down-regulates or inhibits expression of a nucleic acid or amino acid sequence of an AMDP-related or phagocytosis-related gene.
28. (Withdrawn) The method of claim 27, wherein said AMDP-related or phagocytosis-related gene is

Application No. 10/773,446

selected from the group consisting of prostaglandin D2 synthase, MT1-MMP, and AMDP-3, said genes comprising the respective nucleic acid sequences of SEQ ID NOS:2, 15 and 17.

29. (Withdrawn) The method of claim 27, wherein said agent is selected from the group consisting of a ribozyme, an antisense RNA, or an interfering RNA (RNAi) molecule.
30. (Withdrawn) A method of treating a retinal or choroidal degenerative disease or condition in a subject, the method comprising contacting a retinal or choroidal cell of said subject with a vector that includes a nucleic acid encoding a wild type or polymorphic variant of an AMDP-related or phagocytosis-related protein.
31. (Withdrawn) A composition for prevention or treatment of a retinal or choroidal degenerative disease or condition in a subject, the composition comprising an agent that blocks the expression or activity of an AMDP-related or phagocytosis-related protein.
32. (Withdrawn) The composition of claim 31, wherein said protein is MT1-MMP, prostaglandin D2 synthase or AMDP-3.
33. (Withdrawn) A composition for prevention or treatment of a retinal or choroidal degenerative disease or condition in a subject, the composition comprising a vector that includes a nucleic acid encoding a wild type or polymorphic form of an AMDP-related or phagocytosis-related protein.
34. (Withdrawn) The composition of claim 33, wherein said AMDP-related or phagocytosis-related protein is MT1-MMP.
35. (Withdrawn) A nonhuman transgenic animal comprising an isolated nucleic acid construct, said construct causing at least one cell type of said animal to overexpress MT1-

Application No. 10/773,446

MMP, prostaglandin D2 synthase or AMDP-3.

36. (Withdrawn) The transgenic animal of claim 35, wherein said overexpression is conditionally controlled.

37. (Withdrawn) The transgenic animal of claim 36, wherein said cell type is a retinal cell type selected from the group consisting of a photoreceptor, an RPE cell and a Muller cell, or a choroidal cell type selected from the group consisting of an endothelial cell, a smooth muscle cell, a leukocyte, a macrophage, a melanocyte, and a fibroblast.

38. (Withdrawn) A nonhuman transgenic animal comprising an isolated nucleic acid construct, said construct causing at least one cell type of said animal to express a polymorphic variant of an AMDP-related or phagocytosis-related nucleic acid and/or protein.

39. (Withdrawn) The transgenic animal of claim 38, wherein said polymorphic variant is correlated with an increased incidence in a population of humans with AMD, compared to a normal control population.

40-52. (Canceled)

53. (New) The method of claim 1, wherein the nucleic acid sequence of said AMDP-related or phagocytosis-related gene encodes a human MT1-MMP protein, and comprises the sequence set forth as SEQ ID NO:15, or a polymorphic variant thereof.

54. (New) The method of claim 11, wherein said extracellular matrix is in the retina.

55. (New) The method of claim 11, wherein said extracellular matrix is in the choroid.

Application No. 10/773,446

56. (New) The method of claim 11, wherein said extracellular matrix is in the vitreous.
57. (New) The method of claim 15, wherein said antibody is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, a single chain antibody and an Fab fragment.
58. (New) The method of claim 15, wherein said antibody is administered by intraocular injection.
59. (New) The method of claim 57, wherein said antibody is administered to the retina.
60. (New) The method of claim 57, wherein said antibody is administered to the subretinal space.
61. (New) The method of claim 57, wherein said antibody is administered to the choroid.
62. (New) The method of claim 57, wherein said antibody is administered to the vitreous.